In an article, published on Pharmexec, Anaïs Frappé, Amy Morgan and Crystal Leung, review market access opportunities in China through private payers, and how Commercial Health Insurance (CHI) can bring value before, during, and after NRDL inclusion.

Windrose are thrilled to announce two key promotions in our London office. Georgina Powell has been promoted to from Senior Analyst to Consultant and Kate Hogan from Senior Consultant to Engagement Manager.

On August 16th, 2022, President Biden signed the Inflation Reduction Act into law, which will bring reforms to Medicare spending and coverage, impacting manufacturers’ long-term P&MA strategy and payer decision-making.

Windrose Consulting Group’s take on The Foreign Data Problem: Implications of the FDA’s New Criteria for Foreign Data Submissions.

We are pleased to release the next edition of our Windrose Consulting Group: Global News Roundup for Q2 2022.

In this Q&A, we are featuring Daisy Pharoah and her career journey and highlights to date.

Last week during the second session of our P&MA strategy course (a collaboration between Windrose and Cambridge University), our guest Andrew Walker produced this nugget:

“Uncertainty has been weaponised by payers”

A global pharmaceutical company was preparing to file a reimbursement dossier for the prevention of migraine in Canada and Europe.

Mark Kohler promoted to Principal and William Noumba Um to Senior Analyst at Windrose Consulting Group.

On Friday, April 22nd, 2022, Biogen announced that it had withdrawn the marketing application in the EU for aducanumab (Aduhelm), its monoclonal antibody that targets aggregated forms of amyloid beta found in the brains of Alzheimer’s patients.

Our client had recently received EMA approval for a novel androgen receptor inhibitor, indicated within several solid tumors.

We are pleased to release the second edition of our Windrose Consulting Group: Global News Roundup for Q1 2022.

Our client had a Phase III biosimilar for the treatment of febrile neutropenia in the pipeline, with an estimated 5-years to launch

Our client had a late-stage vaccine candidate targeting older adult (OA) respiratory syncytial virus (RSV), and wanted support with its US pricing and access strategy.

The application of biomarkers in therapy areas beyond oncology will likely play an ever-crucial role in developing more targeted therapies in high unmet need indications, while providing payers with new attributes by which to assess a new treatment’s value.

A global pharmaceutical company had a Phase II/III enzyme replacement therapy in development for a rare genetic disorder that targeted symptoms not addressed by current standard of care.

We are delighted to welcome Mattia Belloni as a Senior Consultant at Windrose.

Windrose conducted a pricing, market access and evidence gap assessment across US, EU4 and UK for two novel agents in a muscle weakness disorder

On the 9th March Windrose ran a 1-day workshop for the masters students on the Cambridge University MPhil in Therapeutic Sciences course. The content included ‘Why it’s important to get your P&MA right’, delved into stakeholder decision analysis, the various payer systems & market archetypes, how to optimise the global strategy and communicate value.

This article will describe the cost-containment measures introduced by the new government and how they influence drugs’ pricing and market access potential.